Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Genase Therapeutics B V currently has 1 pending office action. This matter is assigned to 1 distinct examiner, SEITZ, ANTHONY JOSEPH, who is the busiest examiner for the portfolio with 1 pending action. The portfolio involves 1 distinct examiner and 0 distinct art units.
The prosecution profile is concentrated, with 1 pending action being reviewed by a single examiner. This suggests a focus for the company's current patent office activity. Having 1 distinct examiner handle the 1 pending office action ensures a singular point of contact. The 0 distinct art units recorded indicate the current classification status of the pending matter. SEITZ, ANTHONY JOSEPH is responsible for 1 pending office action in this portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEITZ, ANTHONY JOSEPH | 1 | 68.3% | +27.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18833616 | Tetrahydropyranopyrazole Derivatives for the Treatment of Cancer and Viral Infections | SEITZ, ANTHONY JOSEPH | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18833616 | Tetrahydropyranopyrazole Derivatives for the Treatment of Cancer and Viral Infections | SEITZ, ANTHONY JOSEPH | — | §102§103§112DP | Non-Final OA | — | Pending | Jul 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial